Mark De Ridder

Mark De Ridder is a Clinical Professor at the Vrije Universiteit Brussel (VUB) and affiliated with the Research Centre for Digital Medicine at UZ Brussel. He holds roles such as Department Chair and leads projects in advanced radiotherapy techniques. His research focuses on radiotherapy optimization, radiobiology, and immunology-driven cancer treatments. Key projects include markerless SBRT development and FLASH radiotherapy evaluations. He has authored over 550 publications, with h-index 64, and received multiple awards for his contributions. His work bridges technological innovation (e.g., dynamic tumor tracking) with clinical outcomes, emphasizing personalized radiation doses using radiomics and quantitative imaging.

• Affiliations: VUB Faculty of Medicine and Pharmacy, Research Centre for Digital Medicine (UZB)
• Grants: SRP53 (Markerless SBRT), HERC69 (FLASH Radiotherapy)

Research interests include hypoxia in tumors, radiosensitizers (e.g., hydrogen peroxide), and predictive biomarkers for treatment response. He has advised 7 thesis students and collaborates internationally on translational oncology projects. Media coverage highlights his contributions to MRI-guided prostate and rectal cancer therapies.